Superworth

Biogen price to book ratio BIIB

Market value divided by the book value of the company's net assets, since 2009.

Today, Oct 23, 2026
2.0×
10-year median
3.3×
Against its 10-year history
23rd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.0× to 6.2×
Peer median
8.1×

Biogen's price to book ratio is 2.0× as of Oct 23, 2026.

That is below its ten-year median of 3.3×, lower than on 77% of days in the last ten years.

Over that time it ranged from 1.0× in Apr 2025 to 6.2× in Oct 2017.

The median for 10 large drugmakers of a similar size is 8.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.0×1.3×2.0×
20251.4×1.0×1.5×
20241.3×1.3×2.6×
20232.6×2.2×3.3×
20223.1×2.4×3.4×
20213.4×3.2×5.6×
20203.5×3.4×4.7×
20193.9×3.1×5.0×
20184.3×4.1×6.0×
20175.2×4.6×6.2×
20165.1×4.9×6.3×
20156.5×5.0×10.3×
20147.8×6.9×9.5×
20138.1×5.1×8.5×
20125.2×4.3×5.8×
20114.3×2.9×4.8×
20103.2×2.1×3.2×
20092.4×1.9×2.4×

Against its peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

CompanyPrice to book ratio
BIIBBiogen2.0×
JAZZJazz Pharmaceuticals2.9×
BMYBristol-Myers Squibb5.6×
BMRNBiomarin Pharmaceutical1.7×
CORTCorcept Therapeutics13.2×
PTGXProtagonist Therapeutics10.6×
TGTXTG Therapeutics13.7×
PFEPfizer2.0×
ALKSAlkermes plc.4.0×
GILDGilead Sciences16.4×
AMRXAmneal Pharmaceuticals197×
Peer median8.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Biogen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.